UCB SA (UCB.BR) Stock Overview
Europe - EBR:UCB - BE0003739530 - Common Stock
UCB.BR Key Statistics, Chart & Performance
The current stock price of UCB.BR is 258.1 EUR. In the past month the price increased by 26.58%. In the past year, price increased by 48.85%.
UCB.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 50.01 | 660.72B | ||
| 1LLY.MI | ELI LILLY & CO | 49.92 | 659.59B | ||
| ZEG.DE | ASTRAZENECA PLC | 19.12 | 452.83B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 19.05 | 396.36B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.67 | 389.43B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 15.24 | 260.90B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 14.57 | 249.25B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 15.06 | 220.69B | ||
| NOT.DE | NOVARTIS AG-REG | 14.83 | 216.78B | ||
| NOV.DE | NOVO NORDISK A/S-B | 14.49 | 215.08B | ||
| 1SAN.MI | SANOFI | 11.13 | 204.81B | ||
| SAN.PA | SANOFI | 11.12 | 204.57B |
Related stock screener links
About UCB.BR
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9215
Phone: 3225599999
UCB SA / UCB.BR FAQ
What is the stock price of UCB SA today?
The current stock price of UCB.BR is 258.1 EUR. The price decreased by -0.73% in the last trading session.
What is the ticker symbol for UCB SA stock?
The exchange symbol of UCB SA is UCB and it is listed on the Euronext Brussels exchange.
On which exchange is UCB.BR stock listed?
UCB.BR stock is listed on the Euronext Brussels exchange.
What is the price forecast or stock price prediction for UCB SA stock?
25 analysts have analysed UCB.BR and the average price target is 233.58 EUR. This implies a price decrease of -9.5% is expected in the next year compared to the current price of 258.1. Check the UCB SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is UCB SA worth?
UCB SA (UCB.BR) has a market capitalization of 50.20B EUR. This makes UCB.BR a Large Cap stock.
How many employees does UCB SA have?
UCB SA (UCB.BR) currently has 9215 employees.
What are the support and resistance levels for UCB SA (UCB.BR) stock?
UCB SA (UCB.BR) has a support level at 258.09. Check the full technical report for a detailed analysis of UCB.BR support and resistance levels.
Is UCB SA (UCB.BR) expected to grow?
The Revenue of UCB SA (UCB.BR) is expected to grow by 22.68% in the next year. Check the estimates tab for more information on the UCB.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy UCB SA (UCB.BR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of UCB.BR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of UCB.BR, evaluating the profitability, health, valuation and growth aspects
- UCB SA (UCB.BR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- UCB SA (UCB.BR) Sales and EPS estimates to see what analysts future expectations are.
- UCB SA (UCB.BR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- UCB SA (UCB.BR) Insider and Institutional Ownership to learn about the owners and their transactions.
- UCB SA (UCB.BR) Stock Chart to make your own analysis
- UCB SA (UCB.BR) Latest news and press-releases to stay up to date.
Does UCB SA (UCB.BR) stock pay dividends?
UCB SA (UCB.BR) has a dividend yield of 0.37%. The yearly dividend amount is currently 1.36. Check the full fundamental report for a detailed analysis of UCB.BR dividend history, reliability and sustainability.
When does UCB SA (UCB.BR) report earnings?
UCB SA (UCB.BR) will report earnings on 2026-02-25, after the market close.
What is the Price/Earnings (PE) ratio of UCB SA (UCB.BR)?
The PE ratio for UCB SA (UCB.BR) is 40.2. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 258.1 EUR. Check the full fundamental report for a full analysis of the valuation metrics for UCB.BR.
UCB.BR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 94.79% of all stocks.
UCB.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. Both the profitability and the financial health of UCB.BR get a neutral evaluation. Nothing too spectacular is happening here.
UCB.BR Financial Highlights
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.45% | ||
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| Debt/Equity | 0.29 |
UCB.BR Forecast & Estimates
25 analysts have analysed UCB.BR and the average price target is 233.58 EUR. This implies a price decrease of -9.5% is expected in the next year compared to the current price of 258.1.
For the next year, analysts expect an EPS growth of 51.36% and a revenue growth 22.68% for UCB.BR